Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Great Novel Therapeutics Biotech & Medicals Debt-to-EBITDA Related Terms
Great Novel Therapeutics Biotech & Medicals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Novel Therapeutics Biotech & Medicals Debt-to-EBITDA Chart
Great Novel Therapeutics Biotech & Medicals Annual Data
ROCO:7427 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Great Novel Therapeutics Biotech & Medicals Debt-to-EBITDA vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Debt-to-EBITDA of -0.06 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Great Novel Therapeutics Biotech & Medicals. According to the industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #999999 out of 304 companies in the Biotechnology industry.
Is Great Novel Therapeutics Biotech & Medicals' Debt-to-EBITDA too high?
Great Novel Therapeutics Biotech & Medicals' current Debt-to-EBITDA is -0.06. Based on the distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #999999 out of 304 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #999999 out of 304 companies for Debt-to-EBITDA. This places Great Novel Therapeutics Biotech & Medicals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.22, based on 304 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Great Novel Therapeutics Biotech & Medicals. For the Biotechnology industry, the median Debt-to-EBITDA is 1.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Great Novel Therapeutics Biotech & Medicals's current Debt-to-EBITDA is -0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Possible Value Trap. The stock's GF Value™ is NT$108.27, compared to a current price of NT$70.10 — trading 35.3% below its estimated fair value. The current Debt-to-EBITDA is -0.06. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Debt-to-EBITDA is -0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be undervalued.
The current stock price of NT$70.10 is trading 35.3% below its estimated GF Value™ of NT$108.27.
GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Possible Value Trap.
Key valuation signals for ROCO:7427:
Debt-to-EBITDA: -0.06
GF Value™: NT$108.27 vs. price of NT$70.10 (35.3% below fair value)
No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
50GF Score
Get the complete analysis for ROCO:7427
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7427 has been successfully added to your 
